At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of the Effects of LY2605541 and Insulin Glargine on Endogenous Glucose Output and Peripheral Glucose Disposal in Healthy Subjects and Patients With Type 1 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating LY2605541 and Insulin glargine for Healthy Volunteers and Diabetes Mellitus, Type 1. Completed, enrolled 22 participants across 1 site.
Detailed Summary
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, what effect this investigational drug has on the body, and how much should be given. This study will also measure how much of the investigational drug gets into the blood stream and how long it takes the body to get rid of it. The study has 2 parts: Part A will be conducted in healthy participants. Part B will be conducted in participants with type 1 diabetes mellitus (T1DM). This study will take approximately 10-14 days spread over 6-20 weeks, not including screening. Screening will be performed within 30 days of the start of the study.
Study Details
Timeline
Interventions
LY2605541 is a solution. The concentration of LY2605541 is 100 units/milliliter (U/mL).
Insulin glargine is a 100 U/mL solution in 10 milliliter (mL) glass vial.